• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    2/9/24 6:37:13 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRQR alert in real time by email
    SC 13G/A 1 tm245610d1_sc13ga.htm SC 13G/A

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    ProQR Therapeutics N.V.

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.04 per share

    (Title of Class of Securities)

     

    N71542109

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)

     

     

     

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Van Herk Investments B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    7,146,219
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    7,146,219
     
    8 Shared Dispositive Power
    0
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    2

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Van Herk Investments THI B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    3

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Van Herk Private Equity Investments B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    4

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Stichting Administratiekantoor Penulata
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    OO
                   

     

    5

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Van Herk Management Services B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    6

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    7

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    A. van Herk Holding B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    8

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Stichting Administratiekantoor Abchrys
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    OO
                   

     

    9

     

     

    CUSIP No. N71542109 13G  
     
      1 Name of Reporting Person
    Adrianus van Herk
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    7,146,219
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    7,146,219
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    7,146,219
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    8.8%
     
      12 Type of Reporting Person (See Instructions)
    IN
                   

     

    10

     

     

    CUSIP No. N71542109 13G  

     

    Item 1.
      (a) Name of Issuer:
    ProQR Therapeutics N.V., a public company with limited liability incorporated under the laws of the Netherlands
      (b)

    Address of Issuer’s Principal Executive Offices:

    Zernikedreef 9

    2333 CK Leiden

    The Netherlands

     
    Item 2.
      (a)

    Names of Persons Filing:

    This statement is being filed by (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHI”), with respect to Ordinary Shares (as defined below) beneficially owned by it, (ii) Van Herk Investments THI B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHIT”), with respect to Ordinary Shares beneficially owned by VHI, (iii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHPI”), with respect to Ordinary Shares beneficially owned by VHI and VHIT, (iv) Stichting Administratiekantoor Penulata, a foundation organized under the laws of the Netherlands (“Penulata”), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (v) Van Herk Management Services B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHMS”), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (vi) Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., a private company with limited liability incorporated under the laws of the Netherlands (“OGBBA”), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI and VHMS, (vii) A. van Herk Holding B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Holdings”), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS and OGBBA, (viii) Stichting Administratiekantoor Abchrys, a foundation organized under the laws of the Netherlands (“Abchrys”), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA and Holdings, and (ix) Adrianus van Herk (“Mr. van Herk”) with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA, Holdings, Penulata and Abchrys.

     

    Mr. van Herk is (i) an investor, (ii) the holder of all of the depositary receipts issued by Penulata and Abchrys, (iii) the sole board member of Penulata and Abchrys, and (iv) the sole managing director of VHMS, OGBBA and Holdings. Penulata holds substantially all of the issued and outstanding shares of VHPI. VHPI is the sole shareholder of VHIT. VHIT is the sole shareholder of VHI. VHI is principally engaged in making investments. Abchrys holds substantially all of the issued and outstanding shares of Holdings. Holdings is the sole shareholder of OGBBA. OGBBA is the sole shareholder of VHMS and is principally engaged in making investments. VHMS is the sole managing director of VHI, VHIT and VHPI.

     

    Each of Mr. van Herk, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys disclaims beneficial ownership of the securities covered by this statement.

      (b)

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of Mr. van Herk, VHI, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys is:

     

    Lichtenauerlaan 30

    3062 ME Rotterdam

    The Netherlands

      (c) Citizenship:
    Each of VHI, VHIT, VHPI, VHMS, OGBBA and Holdings is a private company with limited liability incorporated under the laws of the Netherlands.  Penulata and Abchrys are Netherlands foundations.  Mr. van Herk is a citizen of the Netherlands.
      (d) Title of Class of Securities:
    Ordinary Shares, nominal value €0.04 per share (the “Ordinary Shares”)
      (e) CUSIP Number:
    N71542109

     

    11

     

     

    CUSIP No. N71542109 13G  

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
        o Broker or dealer registered under section 15 of the Act;
           
        o Bank as defined in section 3(a)(6) of the Act;
           
        o Insurance company as defined in section 3(a)(19) of the Act;
           
        o Investment company registered under section 8 of the Investment Company Act of 1940;
           
        o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
        o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
        o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
        o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
        o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
        o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
        o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________
           
    Item 4. Ownership
     
      (a) Amount beneficially owned:
    7,146,219 shares of Ordinary Shares
      (b) Percent of class:
    8.8% (The percentages used in this statement are calculated based upon the 81,157,493 Ordinary Shares issued and outstanding as reported by the Issuer in its Unaudited Condensed Consolidated Financial Statements for the three and nine month periods ended September 30, 2023 filed with the Securities and Exchange Commission as Exhibit 99.2 to Form 6-K on November 7, 2023.)
      (c) Number of shares as to which such person has:
     
      VHI
        i. Sole power to vote or direct the vote:
    7,146,219
        ii. Shared power to vote or direct the vote:
    0
        iii. Sole power to dispose or direct the disposition of:
    7,146,219
        iv. Shared power to dispose or direct the disposition of:
    0

     

    12

     

     

    CUSIP No. N71542109 13G  

     

      VHI has the sole power to vote or direct the vote, and to dispose or to direct the disposition of, the Ordinary Shares beneficially owned by it.

     

      VHIT
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      VHIT shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in VHI.

     

      VHPI
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      VHPI shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in VHIT.
       
      Penulata
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      Penulata shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in VHPI.
       
      VHMS
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      VHMS shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of it being the sole managing director of VHI, VHIT and VHPI.
       
      OGBBA
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      OGBBA shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in VHMS.
       
      Holdings
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219

     

    13

     

     

    CUSIP No. N71542109 13G  

     

        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      Holdings shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in OGBBA.
       
      Abchrys
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      Abchrys shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of its direct equity interest in Holdings.
       
      Mr. van Herk
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    7,146,219
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    7,146,219
      Mr. van Herk shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Ordinary Shares beneficially owned by VHI by virtue of his holding of all of the depositary receipts issued by Penulata and Abchrys, his being the sole board member of Penulata and Abchrys, and his being the sole managing director of VHMS, OGBBA and Holdings.
       
    Item 5. Ownership Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ¨.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not Applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not Applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
     
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.

     

    14

     

     

    CUSIP No. N71542109 13G  

     

    Item 10. Certification
       
    By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    15

     

     

    CUSIP No. N71542109 13G  

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2023

     

      VAN HERK INVESTMENTS B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK INVESTMENTS THI B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK PRIVATE EQUITY INVESTMENTS B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      STICHTING ADMINISTRATIEKANTOOR PENULATA
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK MANAGEMENT SERVICES B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      ONROEREND GOED BEHEER- EN
      BELEGGINGSMAATSCHAPPIJ A. VAN HERK B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      A. VAN HERK HOLDING B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*

     

     

    * Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

     

    16

     

     

    CUSIP No. N71542109 13G  

     

      STICHTING ADMINISTRATIEKANTOOR ABCHRYS
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      ADRIANUS VAN HERK
       
       
      By: /s/ Erik G.A. Esveld
      Name: Erik G.A. Esveld
      Title: Attorney-In-Fact*

     

     

    * Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

     

    [Signature Page to Schedule 13G]

     

    17

     

     

    CUSIP No. N71542109 13G  

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Title
         
    99.1   Joint Filing Agreement, dated February 8, 2023, by and among the Reporting Persons, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
         
    99.2   Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons, incorporated by reference herein by reference to Exhibit 99.2 to Amendment No. 3 to Schedule 13G filed by the Reporting Persons on September 17, 2019 with respect to Zealand Pharma A/S (File No. 001-38178).

     

    18

     

    Get the next $PRQR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRQR

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

      LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California. "We are excited to share these presentations with the scientific community, demonstrating the breadt

      5/12/25 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces First Quarter 2025 Operating and Financial Results

      Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today r

      5/8/25 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

      LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company's fireside chat will be available from the "Investors & Media" section of ProQR's website under "Events". A replay of the webcast will then be available for approximately 30 days. About Axiomer™ ProQR is pioneering a next-generation RNA base

      5/2/25 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on ProQR Therapeutics with a new price target

      Evercore ISI initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $5.00

      4/29/25 8:12:03 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00

      4/29/25 8:11:53 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00

      3/10/25 7:58:48 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

      SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      2/14/24 6:08:12 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

      SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      2/9/24 6:37:13 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProQR Therapeutics N.V.

      SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)

      9/14/23 5:20:05 PM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    SEC Filings

    See more
    • SEC Form 6-K filed by ProQR Therapeutics N.V.

      6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

      6/3/25 4:11:07 PM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.

      SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      5/12/25 9:07:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ProQR Therapeutics N.V.

      6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

      5/8/25 7:00:17 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Financials

    Live finance-specific insights

    See more
    • ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.  During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its pipeline of development candidates including data updates and next steps on its programs for NTCP and B4GALT1, AX-0810 and AX-1412. Prese

      12/5/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

      ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl

      5/8/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The

      12/22/22 6:15:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Leadership Updates

    Live Leadership Updates

    See more
    • ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

      LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. "We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution," said Daniel A

      4/14/25 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform. Dr. Beal's decades of res

      12/10/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

      LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.  "It is a great honor to have John engaged with ProQR as a strategic advisor to the Supervisory Board to support us in defining the next steps for the Company, while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,"

      3/7/22 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care